Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">mixed_5</font> <font color="blue">dyslipidaemia_5</font> <font color="blue">and_5</font> <font color="blue">metabolic_5</font> <font color="blue">syndrome_5</font> <font color="blue">._5</font> 
<br>
<br> BACKGROUND Raised triglycerides ( TG ) , decreased high - density lipoprotein cholesterol ( HDL - C ) levels and a predominance of small dense low density lipoproteins ( sdLDL ) are characteristics of the <font color="blue">metabolic_2</font> <font color="blue">syndrome_2</font> <font color="blue">(_2</font> <font color="blue">MetS_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> 
<br> OBJECTIVE To compare the effect of high - dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">mixed_3</font> <font color="blue">dyslipidaemia_3</font> <font color="blue">and_3</font> <font color="blue">MetS._3</font> 
<br> METHODS We previously <font color="blue">randomised_1</font> <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">low_3</font> <font color="blue">-_3</font> <font color="blue">density_3</font> <font color="blue">lipoprotein_3</font> <font color="blue">cholesterol_3</font> <font color="blue">(_3</font> <font color="blue">LDL_3</font> <font color="blue">-_3</font> <font color="blue">C_3</font> <font color="blue">)_3</font> <font color="blue">>_3</font> <font color="blue">160_3</font> <font color="blue">and_3</font> <font color="blue">TG_3</font> <font color="blue">>_3</font> <font color="blue">200_3</font> <font color="blue"> _3</font> <font color="blue">mg_3</font> <font color="blue">/_3</font> <font color="blue">dl_3</font> <font color="blue">to_2</font> <font color="blue">rosuvastatin_2</font> <font color="blue">monotherapy_2</font> <font color="blue">40_2</font> <font color="blue"> _2</font> <font color="blue">mg_2</font> <font color="blue">/_2</font> <font color="blue">day_2</font> <font color="blue">(_2</font> <font color="blue">R_2</font> <font color="blue">group_2</font> <font color="blue">,_2</font> <font color="blue">n_3</font> <font color="blue">=_3</font> <font color="blue">30_3</font> <font color="blue">)_3</font> <font color="blue">or_2</font> <font color="blue">rosuvastatin_2</font> <font color="blue">10_2</font> <font color="blue">mg_2</font> <font color="blue">/_2</font> <font color="blue">day_2</font> <font color="blue">combined_2</font> <font color="blue">with_2</font> <font color="blue">fenofibrate_2</font> <font color="blue">200_2</font> <font color="blue">mg_2</font> <font color="blue">/_2</font> <font color="blue">day_2</font> <font color="blue">(_2</font> <font color="blue">RF_2</font> <font color="blue">group_2</font> <font color="blue">,_2</font> <font color="blue">n_3</font> <font color="blue">=_3</font> <font color="blue">30_3</font> <font color="blue">)_3</font> <font color="blue">or_2</font> <font color="blue">ω-3_2</font> <font color="blue">fatty_2</font> <font color="blue">acids_2</font> <font color="blue">2_2</font> <font color="blue">g_2</font> <font color="blue">/_2</font> <font color="blue">day_2</font> <font color="blue">(_2</font> <font color="blue">Rω_2</font> <font color="blue">group_2</font> <font color="blue">,_2</font> <font color="blue">n_3</font> <font color="blue">=_3</font> <font color="blue">30_3</font> <font color="blue">)_3</font> <font color="blue">._2</font> <font color="blue">In_1</font> <font color="blue">the_1</font> <font color="blue">present_1</font> <font color="blue">study_1</font> <font color="blue">,_1</font> <font color="blue">only_3</font> <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">MetS_3</font> <font color="blue">were_3</font> <font color="blue">included_3</font> <font color="blue">(_2</font> <font color="blue">24_2</font> <font color="blue">,_2</font> <font color="blue">23_2</font> <font color="blue">and_2</font> <font color="blue">24_2</font> <font color="blue">in_2</font> <font color="blue">the_2</font> <font color="blue">R_2</font> <font color="blue">,_2</font> <font color="blue">RF_2</font> <font color="blue">and_2</font> <font color="blue">Rω_2</font> <font color="blue">groups_2</font> <font color="blue">respectively_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> At baseline and after 12 weeks of treatment , the lipoprotein subfraction profile was determined by polyacrylamide 3% gel electrophoresis . 
<br> RESULTS The mean LDL size was significantly increased in all groups . This change was more prominent with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05 compared with R and Rω ) . A decrease in insulin resistance by RF was also noted . Only RF significantly raised HDL - C levels ( by 7.7% , p < 0.05 ) by increasing the cholesterol of small HDL particles . The cholesterol of larger HDL subclasses was significantly increased by R and Rω. 
<br> CONCLUSIONS All regimens increased mean LDL size ; RF was the most effective . A differential effect of treatments was noted on the HDL subfraction profile .